molsidomine has been researched along with Parkinson Disease in 8 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)." | 7.73 | Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006) |
| "We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MT(dko)) mice, metallothionein-transgenic (MT(trans)) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO(-)-induced neurodegeneration in Parkinson disease (PD)." | 3.73 | Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. ( Ebadi, M; Sharma, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solís, O | 1 |
| Espadas, I | 1 |
| Del-Bel, EA | 1 |
| Moratalla, R | 1 |
| Di Matteo, V | 1 |
| Pierucci, M | 1 |
| Benigno, A | 1 |
| Crescimanno, G | 1 |
| Esposito, E | 1 |
| Di Giovanni, G | 1 |
| Hung, LW | 1 |
| Villemagne, VL | 1 |
| Cheng, L | 1 |
| Sherratt, NA | 1 |
| Ayton, S | 1 |
| White, AR | 1 |
| Crouch, PJ | 1 |
| Lim, S | 1 |
| Leong, SL | 1 |
| Wilkins, S | 1 |
| George, J | 1 |
| Roberts, BR | 1 |
| Pham, CL | 1 |
| Liu, X | 1 |
| Chiu, FC | 1 |
| Shackleford, DM | 1 |
| Powell, AK | 1 |
| Masters, CL | 1 |
| Bush, AI | 1 |
| O'Keefe, G | 1 |
| Culvenor, JG | 1 |
| Cappai, R | 1 |
| Cherny, RA | 1 |
| Donnelly, PS | 1 |
| Hill, AF | 1 |
| Finkelstein, DI | 1 |
| Barnham, KJ | 1 |
| Lev, N | 1 |
| Melamed, E | 1 |
| Offen, D | 1 |
| Jiang, H | 1 |
| Wu, YC | 1 |
| Nakamura, M | 1 |
| Liang, Y | 1 |
| Tanaka, Y | 1 |
| Holmes, S | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Ross, CA | 1 |
| Smith, WW | 1 |
| Ebadi, M | 1 |
| Sharma, S | 1 |
| Krzaścik, P | 1 |
| Kostowski, W | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
8 other studies available for molsidomine and Parkinson Disease
| Article | Year |
|---|---|
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dop | 2015 |
Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study .
Topics: Animals; Corpus Striatum; Indazoles; Male; Molsidomine; Nitric Oxide; Nitric Oxide Donors; Oxidopami | 2009 |
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Cognition; Coordination Complexes; Disease Models, Anima | 2012 |
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Topics: alpha-Synuclein; Benzothiazoles; Cell Differentiation; Cell Line, Tumor; Cytoplasm; Ferrous Compound | 2006 |
Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Topics: alpha-Synuclein; Animals; Cell Death; Dose-Response Relationship, Drug; Genetic Predisposition to Di | 2007 |
Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Coenzymes; Dopamine; Enzyme Activation; Lipid Peroxidation; | 2006 |
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide S | 1997 |
Future of neuroprotection in Parkinson's disease.
Topics: Apoptosis; Humans; Molsidomine; Neuroprotective Agents; Neurotoxins; Nitric Oxide Donors; Oxidopamin | 2001 |